Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efdamrofusp alfa in wet AMD
NCT03814291Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Apr 2019
- Primary completion
- Mar 2020
- Modality
- Bispecific Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of efdamrofusp alfa in exudative macular degeneration (6 cohorts), sponsored by Innovent Biologics. Primary endpoint: Safety evaluation indicators at Day 43. Started Apr 2019; status: completed.
02
Drugs
efdamrofusp alfa
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT03814291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03814291.